Literature DB >> 25658256

Pivotal trials for β-secretase inhibitors in Alzheimer's.

Cormac Sheridan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25658256     DOI： 10.1038/nbt0215-115

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  4 in total

1.  Genentech's Alzheimer's antibody trial to study disease prevention.

Authors:  Ken Garber
Journal:  Nat Biotechnol       Date:  2012-08       Impact factor: 54.908

2.  Anti-Aβ antibody target engagement: commentary regarding Watt et al. Acta Neuropathol 127:803-810 (2014).

Authors:  Eric Siemers; Robert A Dean; Ronald B DeMattos; Michael L Hutton; Kaj Blennow; Leslie M Shaw; David M Holtzman
Journal:  Acta Neuropathol       Date:  2014-08-14       Impact factor: 17.088

3.  Lessons from a failed γ-secretase Alzheimer trial.

Authors:  Bart De Strooper
Journal:  Cell       Date:  2014-11-06       Impact factor: 41.582

4.  Do current therapeutic anti-Aβ antibodies for Alzheimer's disease engage the target?

Authors:  Andrew D Watt; Gabriela A N Crespi; Russell A Down; David B Ascher; Adam Gunn; Keyla A Perez; Catriona A McLean; Victor L Villemagne; Michael W Parker; Kevin J Barnham; Luke A Miles
Journal:  Acta Neuropathol       Date:  2014-05-07       Impact factor: 17.088
  4 in total
  6 in total

1.  Everything but amyloid: new thinking prompts FDA revamp.

Authors:  Eva von Schaper
Journal:  Nat Biotechnol       Date:  2018-06-06       Impact factor: 54.908

2.  Hope for anti-amyloid antibodies surges, yet again.

Authors:  Chris Morrison
Journal:  Nat Biotechnol       Date:  2016-11-08       Impact factor: 54.908

3.  Development of 2-aminooxazoline 3-azaxanthene β-amyloid cleaving enzyme (BACE) inhibitors with improved selectivity against Cathepsin D.

Authors:  Jonathan D Low; Michael D Bartberger; Kui Chen; Yuan Cheng; Mark R Fielden; Vijay Gore; Dean Hickman; Qingyian Liu; E Allen Sickmier; Hugo M Vargas; Jonathan Werner; Ryan D White; Douglas A Whittington; Stephen Wood; Ana E Minatti
Journal:  Medchemcomm       Date:  2017-04-27       Impact factor: 3.597

Review 4.  A multitude of signaling pathways associated with Alzheimer's disease and their roles in AD pathogenesis and therapy.

Authors:  Kundlik Gadhave; Deepak Kumar; Vladimir N Uversky; Rajanish Giri
Journal:  Med Res Rev       Date:  2020-08-11       Impact factor: 12.388

Review 5.  Potential neuroprotective properties of epigallocatechin-3-gallate (EGCG).

Authors:  Neha Atulkumar Singh; Abul Kalam Azad Mandal; Zaved Ahmed Khan
Journal:  Nutr J       Date:  2016-06-07       Impact factor: 3.271

6.  Biotic/Abiotic Stress-Driven Alzheimer's Disease.

Authors:  Chang-Qing Li; Qing Zheng; Qi Wang; Qing-Ping Zeng
Journal:  Front Cell Neurosci       Date:  2016-11-23       Impact factor: 5.505
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.